Clover Biopharmaceuticals announced it has received Clinical Trial Application (CTA) approval from the Chinese Food and Drug Administration (CFDA) to conduct clinical trials in China with SCB-808, a proposed biosimilar of Enbrel (etanercept). The drug is being developed in the prefilled syringe formulation for the treatment of rheumatoid arthritis and other autoimmune diseases.    “We are delighted to receive this clearance, as it further validates Clover’s in-house cGMP biomanufacturing...